Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Mar 15;146(6):1503-1513.
doi: 10.1002/ijc.32486. Epub 2019 Jun 20.

Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial

Nikolaus Becker  1 , Erna Motsch  1 , Anke Trotter  1 , Claus P Heussel  2   3   4 , Hendrik Dienemann  4   5 , Philipp A Schnabel  4   6 , Hans-Ulrich Kauczor  3   4 , Sandra González Maldonado  1   4 , Anthony B Miller  7 , Rudolf Kaaks  1   4 , Stefan Delorme  4   8
Affiliations
Randomized Controlled Trial

Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial

Nikolaus Becker et al. Int J Cancer. .

Abstract

In 2011, the U.S. National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these first findings from European trials that started in parallel with the NLST. The German Lung cancer Screening Intervention (LUSI) is a randomized trial among 4,052 long-term smokers, 50-69 years of age, recruited from the general population, comparing five annual rounds of LDCT screening (screening arm; n = 2,029 participants) with a control arm (n = 2,023) followed by annual postal questionnaire inquiries. Data on lung cancer incidence and mortality and vital status were collected from hospitals or office-based physicians, cancer registries, population registers and health offices. Over an average observation time of 8.8 years after randomization, the hazard ratio for lung cancer mortality was 0.74 (95% CI: 0.46-1.19; p = 0.21) among men and women combined. Modeling by sex, however showed a statistically significant reduction in lung cancer mortality among women (HR = 0.31 [95% CI: 0.10-0.96], p = 0.04), but not among men (HR = 0.94 [95% CI: 0.54-1.61], p = 0.81) screened by LDCT (pheterogeneity = 0.09). Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men. This heterogeneity could be the result of different relative counts of lung tumor subtypes occurring in men and women.

Keywords: cancer low-dose CT; lung; randomized trial; screening.

PubMed Disclaimer

References

    1. Field JK, van Klaveren R, Pedersen JH, et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol 2013;108:280-6.
    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
    1. Field JK. Perspective: the screening imperative. Nature 2014;513:S7.
    1. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014;160:330-8.
    1. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-9.

Publication types